Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World multiple myeloma treatment outcomes under the microscope

NCT ID NCT01838512

Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is observing over 2,500 people with multiple myeloma to see how well approved treatments work in real-world settings, not just in controlled trials. It includes both newly diagnosed patients and those whose cancer has come back or stopped responding to treatment. The goal is to track survival, treatment patterns, and healthcare use to better understand what happens outside of clinical studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,555 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2012

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of two cohorts: Participants with relapsed/refractory (RR) multiple myeloma (MM) and those with newly-diagnosed (ND) multiple myeloma (MM).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: For RRMM participants who have received at least one prior line of therapy (LoT) for MM: * Have documented progression from a prior LoT * Participants who have initiated treatment with one of the following therapies within 90 days before consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before consent for this study must be provided, and treatment must be initiated within 30 days after consent: * IMiDs * PIs * Combination of IMiD + PI * Newer agents with novel MOAs alone or in combination (eg, mAbs, HDACIs, Akt inhibitors, SINE, or CAR T-cell therapies) For NDMM participants receiving frontline therapy: * Eligible to receive frontline therapy for MM (no prior MM treatment) * Participants who have initiated treatment for MM with one of the following therapies within 90 days before consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before consent for this study must be provided, and treatment must be initiated within 30 days after consent: * IMiDs * PIs * Combination of IMiD + PI * Newer agents with novel MOAs alone or in combination (eg, mAbs, HDACIs, Akt inhibitors, SINE, or CAR T-cell therapies) Exclusion Criteria: * Participants who are currently participating in a clinical trial for MM * Participants who are currently receiving treatment for primary cancer other than MM * Participants who are not willing or able to provide informed consent * Participants who are incarcerated * Participants under compulsory detention for treatment of a physical (eg, infectious) or psychiatric illness Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • Local Institute

    Goodyear, Arizona, 85338, United States

  • Local Institute

    Los Angeles, California, 90013, United States

  • Local Institute

    Santa Rosa, California, 95403, United States

  • Local Institute

    Valdosta, Georgia, 31602, United States

  • Local Institute

    Sioux City, Iowa, 51101, United States

  • Local Institute

    Louisville, Kentucky, 40201, United States

  • Local Institute

    Southaven, Mississippi, 38671, United States

  • Local Institute

    Kansas City, Missouri, 64132, United States

  • Local Institute

    Saint Joseph, Missouri, 64501, United States

  • Local Institute

    Missoula, Montana, 59802, United States

  • Local Institute

    Missoula, Montana, 59807, United States

  • Local Institute

    Omaha, Nebraska, 68124, United States

  • Local Institute

    Cary, North Carolina, 27518, United States

  • Local Institute

    Canton, Ohio, 44718, United States

  • Local Institute

    Cleveland, Ohio, 44109-1900, United States

  • Local Institute

    Tulsa, Oklahoma, 74136, United States

  • Local Institute

    Portland, Oregon, 97200, United States

  • Local Institute

    Pottstown, Pennsylvania, 19464, United States

  • Local Institute

    Charleston, South Carolina, 29414, United States

  • Local Institute

    Knoxville, Tennessee, 37920, United States

  • Local Institute

    Amarillo, Texas, 79106, United States

  • Local Institute

    Corpus Christi, Texas, 78350, United States

  • Local Institute

    Dallas, Texas, 75229, United States

  • Local Institute

    Dallas, Texas, 75231, United States

  • Local Institute

    Dallas, Texas, 75390, United States

  • Local Institute

    San Antonio, Texas, 78217, United States

  • Local Institute

    Sherman, Texas, 75090, United States

  • Local Institute

    Seattle, Washington, 98101, United States

  • Local Institute

    Spokane, Washington, 99202, United States

  • Local Institute

    Yakima, Washington, 98901, United States

  • Local Institute

    Yakima, Washington, 98902, United States

  • Local Institute

    Toronto, Ontario, M4N 3M5, Canada

  • Local Institute

    Weston, Ontario, M9N 1N8, Canada

  • Local Institute

    Blois, France

  • Local Institute

    Chalon-sur-Saône, France

  • Local Institute

    La Roche-sur-Yon, France

  • Local Institute

    Limoges, France

  • Local Institute

    Meaux, France

  • Local Institute

    Nantes, France

  • Local Institute

    Rennes, 35033, France

  • Local Institute

    Heidelberg, Baden-Wurttemberg, 69120, Germany

  • Local Institute

    Hamm, North Rhine-Westphalia, 59071, Germany

  • Local Institute

    Aschaffenburg, 63739, Germany

  • Local Institute

    Berlin, 10407, Germany

  • Local Institute

    Dresden, 01099, Germany

  • Local Institute

    Magdeburg, 39104, Germany

  • Local Institute

    München, Germany

  • Local Institute

    Rostock, Germany

  • Local Institute

    Pesaro, Pesaro E Urbino, 61122, Italy

  • Local Institute

    Ancona, 042002, Italy

  • Local Institute

    Ancona, 60126, Italy

  • Local Institute

    Cagliari, B354, Italy

  • Local Institute

    Florence, 50139, Italy

  • Local Institute

    Lecce, 73100, Italy

  • Local Institute

    Milan, 20121, Italy

  • Local Institute

    Naples, 80136, Italy

  • Local Institute

    Roma, 00161, Italy

  • Local Institute

    Terni, 5100, Italy

  • Local Institute

    Torino, 10126, Italy

  • Local Institute

    Vicenza, 36100, Italy

  • Local Institute

    Truro, Cornwall, TR1 3LJ, United Kingdom

  • Local Institute

    Leeds, LS9 7TF, United Kingdom

  • Local Institute

    Nottingham, NG5 1PB, United Kingdom

  • Local Institute

    Stafford, ST16 3SA, United Kingdom

  • Local Institute

    Swansea, SA2 8QA, United Kingdom

  • Local Institution

    Birmingham, Alabama, 35213, United States

  • Local Institution

    Anaheim, California, 92801, United States

  • Local Institution

    Corona, California, 92880, United States

  • Local Institution

    Brooksville, Florida, 34613, United States

  • Local Institution

    Jacksonville, Florida, 32256, United States

  • Local Institution

    Skokie, Illinois, 60077, United States

  • Local Institution

    Indianapolis, Indiana, 46237, United States

  • Local Institution

    Lafayette, Louisiana, 70503, United States

  • Local Institution

    Shreveport, Louisiana, 71103, United States

  • Local Institution

    Minneapolis, Minnesota, 55404, United States

  • Local Institution

    Springfield, Missouri, 65804, United States

  • Local Institution

    St Louis, Missouri, 63110, United States

  • Local Institution

    Gastonia, North Carolina, 28054, United States

  • Local Institution

    Memphis, Tennessee, 38120, United States

  • Local Institution

    Roma, 00189, Italy

  • Local Institution

    Liverpool, L7 8XP, United Kingdom

  • Local Institution - 0010

    Gastonia, North Carolina, 28054, United States

  • Local Institution - 0011

    Indianapolis, Indiana, 46237, United States

  • Local Institution - 0014

    Dallas, Texas, 75390, United States

  • Local Institution - 0016

    Charleston, South Carolina, 29414, United States

  • Local Institution - 0020

    Springfield, Missouri, 65804, United States

  • Local Institution - 0022

    Canton, Ohio, 44718, United States

  • Local Institution - 0023

    Anaheim, California, 92801, United States

  • Local Institution - 0024

    Omaha, Nebraska, 68124, United States

  • Local Institution - 0025

    Dallas, Texas, 75231, United States

  • Local Institution - 0026

    Spokane, Washington, 99202, United States

  • Local Institution - 0027

    San Antonio, Texas, 78217, United States

  • Local Institution - 0030

    Woodbury, Minnesota, 55125, United States

  • Local Institution - 0031

    Yakima, Washington, 98902, United States

  • Local Institution - 0032

    Garland, Texas, 75042, United States

  • Local Institution - 0033

    Cary, North Carolina, 27518, United States

  • Local Institution - 0037

    Missoula, Missouri, 59802, United States

  • Local Institution - 0041

    Springfield, Illinois, 62794-9677, United States

  • Local Institution - 0042

    Louisville, Kentucky, 40202, United States

  • Local Institution - 0044

    Fort Lauderdale, Florida, 33308, United States

  • Local Institution - 0045

    Burbank, California, 91505, United States

  • Local Institution - 0047

    Valdosta, Georgia, 31602, United States

  • Local Institution - 0048

    Downey, California, 90241, United States

  • Local Institution - 0049

    Stony Brook, New York, 11794, United States

  • Local Institution - 0050

    Kansas City, Missouri, 64132, United States

  • Local Institution - 0051

    Santa Rosa, California, 95403, United States

  • Local Institution - 0052

    Fountain Valley, California, 92708, United States

  • Local Institution - 0058

    Anderson, Indiana, 46016, United States

  • Local Institution - 0066

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 0067

    Magdeburg, 39104, Germany

  • Local Institution - 0070

    Hamm, 59071, Germany

  • Local Institution - 0085

    Wiesbaden, 65191, Germany

  • Local Institution - 0095

    Nottingham, NG5 1PB, United Kingdom

  • Local Institution - 0100

    La Roche-sur-Yon, 85925, France

  • Local Institution - 0107

    Terni, 05100, Italy

  • Local Institution - 0111

    Florence, 50134, Italy

  • Local Institution - 0112

    Torino, 10126, Italy

  • Local Institution - 0114

    Naples, 80139, Italy

  • Local Institution - 0115

    Pesaro, 61122, Italy

  • Local Institution - 0116

    Milan, 20133, Italy

  • Local Institution - 0117

    Vicenza, 36100, Italy

  • Local Institution - 0119

    Cagliari, 09121, Italy

  • Local Institution - 0120

    Messina, 98122, Italy

  • Local Institution - 0121

    Pescara, 65124, Italy

  • Local Institution - Canada

    No City Provided, New Jersey, 00000, United States

  • Local Institution - France

    No City Provided, New Jersey, 00000, United States

  • Local Institution - Germany

    No City Provided, New Jersey, 00000, United States

  • Local Institution - Italy

    No City Provided, New Jersey, 00000, United States

  • Local Institution - USA

    No City Provided, New Jersey, 00000, United States

  • Local Institution - United Kingdom

    No City Provided, New Jersey, 00000, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.